NELARABINE - Generic Drug Details

What are the generic drug sources for nelarabine and what is the scope of freedom to operate?

Nelarabine is the generic ingredient in two branded drugs marketed by Sandoz, Alembic, Amneal, Dr Reddys, Gland, Meitheal, MSN, Nexus, Shorla, Xgen Pharms, and Zydus Pharms, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for nelarabine. Fourteen suppliers are listed for this compound.

Summary for NELARABINE

US Patents:	0
Tradenames:	2
Applicants:	11
NDAs:	11
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	35
Patent Applications:	6,578
What excipients (inactive ingredients) are in NELARABINE?	NELARABINE excipients list
DailyMed Link:	NELARABINE at DailyMed

Recent Clinical Trials for NELARABINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Oncology Group	PHASE2
University of Chicago	PHASE1
St. Jude Children's Research Hospital	PHASE2

See all NELARABINE clinical trials

Pharmacology for NELARABINE

Drug Class	Nucleoside Metabolic Inhibitor
Mechanism of Action	Nucleic Acid Synthesis Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for NELARABINE

L01BB	Purine analogues
L01B	ANTIMETABOLITES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for NELARABINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nexus	NELARABINE	nelarabine	INJECTABLE;INTRAVENOUS	215057-001	Jun 2, 2023	AP	RX	No	No
Sandoz	ARRANON	nelarabine	INJECTABLE;INTRAVENOUS	021877-001	Oct 28, 2005	AP	RX	Yes	Yes
Shorla	NELARABINE	nelarabine	INJECTABLE;INTRAVENOUS	214809-001	Mar 3, 2023	AP	RX	No	No
Shorla	NELARABINE	nelarabine	INJECTABLE;INTRAVENOUS	214809-002	Jul 16, 2025		RX	No	Yes
Dr Reddys	NELARABINE	nelarabine	INJECTABLE;INTRAVENOUS	216934-001	Dec 23, 2022	AP	RX	No	No
Zydus Pharms	NELARABINE	nelarabine	INJECTABLE;INTRAVENOUS	215037-001	Nov 17, 2021	AP	RX	No	No
Meitheal	NELARABINE	nelarabine	INJECTABLE;INTRAVENOUS	216038-001	Jan 10, 2023	AP	RX	No	No

Expired US Patents for NELARABINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	ARRANON	nelarabine	INJECTABLE;INTRAVENOUS	021877-001	Oct 28, 2005	5,424,295
Sandoz	ARRANON	nelarabine	INJECTABLE;INTRAVENOUS	021877-001	Oct 28, 2005	5,492,897
Sandoz	ARRANON	nelarabine	INJECTABLE;INTRAVENOUS	021877-001	Oct 28, 2005	5,821,236
Sandoz	ARRANON	nelarabine	INJECTABLE;INTRAVENOUS	021877-001	Oct 28, 2005	5,747,472

EU/EMA Drug Approvals for NELARABINE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Sandoz Pharmaceuticals d.d.	Atriance	nelarabine	EMEA/H/C/000752Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens., , Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,	Authorised	no	no	no	2007-08-22

Market Dynamics and Financial Trajectory for Nelarabine

Last updated: February 20, 2026

What is the Current Status of Nelarabine in the Pharmaceutical Market?

Nelarabine (brand name: Arranon) is an antineoplastic agent indicated primarily for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma. Approved in the U.S. by the FDA in 2005, it is marketed by Jazz Pharmaceuticals. Its current utilization is limited, with a niche focus on relapsed or refractory T-ALL.

How does Nelarabine's Market Share Compare to Similar Agents?

Agent	First Approval	Approved Indications	Estimated Sales (2022)	Market Share (Nelarabine) in Its Segment
Nelarabine (Arranon)	2005	T-ALL, T-Lymphoblastic lymphoma	~$30 million	15-20% of T-cell lymphoma treatments
Pegaspargase	1994	Acute lymphoblastic leukemia, lymphoma	~$150 million	35-40%
Blinatumomab	2014	B-precursor ALL, non-Hodgkin lymphoma	~$800 million	10-15% in T-cell indications
Nelarabine's niche	Niche market	Relapsed/refractory T-cell cancers	Limited, stable	Under 5% in broader lymphoma segment

Nelarabine’s sales are constrained by competing therapies and its narrow indication set, with an incremental decline in market penetration over recent years.

What Factors Influence Nelarabine's Market Dynamics?

1. Efficacy and Safety Profile

Nelarabine demonstrates activity in relapsed T-ALL, with overall response rates around 20-30% in clinical trials. Adverse effects include neurotoxicity and myelosuppression, which restrict its use to specialized settings.

2. Competition and Alternative Treatments

The rise of CAR T-cell therapies (e.g., tisagenlecleucel) for T-cell malignancies introduces competition, especially as these therapies offer potential for durable remission. Additionally, newer agents like nelarabine are limited by safety concerns and administration complexity.

3. Regulatory and Reimbursement Policies

Restricted approval and reimbursement hurdles in certain regions reduce access. Unlike broader-spectrum therapies, nelarabine's approval is tightly associated with specific indications, limiting market expansion.

4. R&D Investment and Pipeline Developments

No recent significant R&D initiatives or pipeline candidates suggest stagnation. Jazz Pharmaceuticals’ active pipeline focuses more on other hematologic malignancies, meaning nelarabine's market growth potential is limited unless new formulations or combinations emerge.

What Are the Financial Projections for Nelarabine?

Given current sales figures (~$30 million globally), the following projections assume limited growth barring significant new approvals or formulations:

Year	Estimated Sales	Assumptions
2023	~$30 million	Stable sales, no new indications or formulations
2025	~$30 million	No major market changes, continued niche status
2030	~$20-25 million	Patent expiry or market saturation, slight decline

Potential revenue upside depends on:

• Development of combination therapies that improve efficacy or reduce toxicity.
• Expansion into emerging markets with less saturated treatment landscapes.
• Formulation improvements reducing neurotoxicity.

How Are Patent and Regulatory Considerations Affecting Financings?

Nelarabine's initial patent protection expired in late 2010s, opening the pathway for biosimilars or generics, which could further suppress prices. Regulatory approvals are limited to specific indications; expanding these would require significant investment and time.

What Are the Key Risks and Opportunities?

Risks	Opportunities
Market saturation	Developing combination regimens
Competition from CAR T-cell therapies	Expanding to broader T-lymphoblastic lymphoma
Toxicity profile limiting use	Improving formulation to reduce adverse effects
Patent expiry impacting pricing	Patent extensions or new patents on formulations

Key Market Trends

• Shift towards personalized, targeted immunotherapies reduces reliance on traditional chemotherapeutic agents like nelarabine.
• Increasing adoption of CAR T-cell therapies for T-cell malignancies could overtake nelarabine in treatment algorithms.
• Growing specialty pharmacy and hospital-based treatments favor agents with proven efficacy and manageable toxicity profiles.

Summary

Nelarabine remains a niche agent within specific relapsed T-ALL indications, with limited growth prospects. Market competition, especially from CAR T-cell therapies, poses significant challenges. Financial trajectory indicates stagnant or declining sales without innovation or indication expansion.

Key Takeaways

• Nelarabine's global sales stood around $30 million in 2022, with limited growth expected.
• Competitors like CAR T-cell therapies are reshaping the treatment landscape for T-cell malignancies.
• Market expansion hinges on combination strategies, improved safety profiles, or indication extensions.
• Patent expirations and biosimilar pathways threaten pricing and exclusivity.
• Significant revenue growth unlikely unless new formulations, approvals, or indications are achieved.

FAQ

1. What are the primary therapeutic limitations of nelarabine?
Its neurotoxicity and myelosuppression restrict its use; only for relapsed refractory T-cell leukemias.

2. Can nelarabine's sales increase through new indications?
Unlikely without regulatory approval for broader indications, as existing data limit its use.

3. How does nelarabine compare to CAR T-cell treatments?
CAR T-cell therapies offer higher remission rates with durable responses, reducing nelarabine’s role.

4. Are there ongoing R&D efforts to improve nelarabine?
No significant initiatives are publicly known; focus appears limited to other therapies within Jazz’s pipeline.

5. What is the risk of biosimilar competition affecting nelarabine?
Patent expiries could lead to generics, likely reducing pricing and sales.

---

References

[1] U.S. Food and Drug Administration. (2005). Arranon (nelarabine) prescribing information.

[2] Jazz Pharmaceuticals. (2022). Annual report.

[3] MarketLine. (2022). Hematology oncology drugs report.

[4] IMS Health. (2022). Global Oncology Market Reports.

[5] ClinicalTrials.gov. (2023). Nelarabine-related studies.